GlassScriptPhysician profile
Hamid Banooni
NPI 1922082437
$5,934.49
in general payments reported to CMS, 2019-2025
40 companies · $870 in 2025
The $870 reported for 2025 was more than what 89% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,023 · 2020: $354 · 2021: $730 · 2022: $1,135 · 2023: $1,141 · 2024: $681 · 2025: $870.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,692.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,692.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,092.56 | 2019-2025 | Lo Loestrin Fe, Liletta, Orilissa |
| Sumitomo Pharma America, INC. | $585.59 | 2023-2025 | Myfembree, Gemtesa |
| Coopersurgical, INC. | $422.16 | 2019-2025 | Paragard T 380a, Endosee, Paragard T 380a |
| Hologic Sales and Service, LLC | $410.16 | 2019-2025 | Acessa Provu System, Myosure Tissue Removal Device, Fluent Fluid Management System |
| Mayne Pharma Commercial LLC | $396.43 | 2021-2025 | |
| Myovant Sciences INC. | $392.64 | 2021-2022 | |
| Daiichi Sankyo INC. | $218.96 | 2019-2025 | Injectafer |
| Astellas Pharma US INC | $218.11 | 2023-2025 | Veozah, Myrbetriq |
| Amgen INC. | $205.45 | 2019-2023 | Evenity, Prolia |
| Shield Therapeutics INC | $190.73 | 2023-2025 | Accrufer |
| Pfizer INC. | $170.86 | 2019-2025 | |
| Exeltis, USA INC. | $157.26 | 2019-2025 | Slynd |
| Therapeuticsmd, INC. | $149.65 | 2019-2022 | |
| Organon LLC | $134.98 | 2021-2025 | Nexplanon, Nuvaring |
| Covidien LP | $129.58 | 2019-2020 |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gynesonics, INC. | $127.02 | 2023-2025 | Sonata Sonography-Guided Transcervical Fibroid Ablation System, Sonata Sonography-Guided Transcervical Fibroid Ablation System |
| Astrazeneca Pharmaceuticals LP | $111.79 | 2019 | |
| Allergan, INC. | $110.73 | 2019-2022 | |
| Millicent US INC | $71.42 | 2025 | Femlyv |
| Meditrina | $65.85 | 2022-2024 | |
| Mylan Pharmaceuticals INC. | $56.23 | 2020-2022 | |
| Agile Therapeutics, INC. | $55.63 | 2021-2022 | |
| Channel Medsystems, INC. | $54.88 | 2025 | |
| Evofem Biosciences, INC. | $53.51 | 2021-2022 | |
| Sage Therapeutics, LLC | $47.26 | 2025 | Zurzuvae |
| Amag Pharmaceuticals, INC. | $42.54 | 2019 | |
| Avion Pharmaceuticals | $39.39 | 2019-2020 | |
| Exact Sciences Corporation | $37.84 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Ascend Therapeutics US, LLC | $28.95 | 2021 | |
| Virtus Pharmaceuticals LLC | $25.62 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $18.10 | 2020 | |
| Medicem INC. | $18.01 | 2023 | |
| Scynexis, INC. | $16.81 | 2022 | |
| Minerva Surgical, INC | $14.67 | 2023 | |
| Seqirus USA INC | $13.97 | 2022 | |
| Merck Sharp & Dohme LLC | $12.58 | 2020 | |
| Becton, Dickinson and Company | $12.37 | 2021 | |
| Lupin INC. | $12.13 | 2020 | |
| Acessa Health INC. | $12.07 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$1.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hamid Banooni listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.